Navigation Links
Lilly Reports Third-Quarter 2013 Results
Date:10/23/2013

cisplatin as a first-line treatment, as compared to chemotherapy alone.
  • The company announced plans to supplement its annual dividend with share repurchases totaling $5 billion over time.
  • The company expressed its disappointment with the Centers for Medicare & Medicaid Services final decision to provide Coverage with Evidence Development for beta-amyloid imaging agents, including Amyvid™. The company believes the Medicare coverage decision for these agents is a significant setback for patients and the Alzheimer's disease community.
  • Third-Quarter Reported Results
    In the third quarter of 2013, worldwide total revenue was $5.773 billion, an increase of 6 percent compared with the third quarter of 2012. Revenue growth was comprised of 3 percent due to higher volume and 5 percent due to higher prices, partially offset by a decrease of 2 percent due to the unfavorable impact of foreign exchange rates. The increase in volume was driven by Humalog®, Alimta®, Trajenta® and Forteo®, as well as Animal Health, partially offset by volume declines for Zyprexa® and Cymbalta®. Total revenue in the U.S. increased 11 percent to $3.312 billion driven by increased prices, primarily for Cymbalta. Total revenue outside the U.S. was relatively flat at $2.461 billion, as higher volume was largely offset by the unfavorable impact of the depreciation of the Japanese yen.

    Gross margin increased 8 percent to $4.575 billion in the third quarter of 2013, as growth in other products offset the loss of patent exclusivity for Zyprexa. Gross margin as a percent of total revenue was 79.2 percent, an increase of 1.3 percentage points compared with the third quarter of 2012. The increase in gross margin percent was due to higher prices and lower manufacturing costs, partially offset by the impact of foreign exchange rates on international inventories sold.
    '/>"/>

    SOURCE Eli Lilly and Company
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

    Related medicine technology :

    1. FDA Grants Lillys Ramucirumab Priority Review as a Potential Single-Agent Treatment for Advanced Gastric Cancer
    2. Lilly Declares Fourth-Quarter 2013 Dividend
    3. Lilly Reintegration Scholarship Applications Available for 2014-2015 Academic Year
    4. Lilly to host investment community meeting at its Indianapolis headquarters on Thursday, October 3, 2013
    5. Data Presented at 49th EASD Annual Meeting Show Treatment with Lillys Investigational Dulaglutide Resulted in Improved Patient-Reported Health Outcomes
    6. Lilly Announces Second Positive Ramucirumab Phase III Gastric Cancer Study Meets Primary Endpoint; Phase III Lilly/TRIO Breast Cancer Study Misses Primary Endpoint
    7. Exosome Diagnostics Enters Collaboration Agreement with Lilly for Exosome Blood-Based Biomarker Discovery
    8. Lilly to Present Data Across its Diabetes Portfolio at the 49th European Association for the Study of Diabetes Annual Meeting
    9. Humana and Lilly Form Research Collaboration to Improve Health Care Outcomes
    10. Dr. Marschall S. Runge Elected to Lilly Board of Directors
    11. Lilly Reports Second-Quarter 2013 Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/22/2014)... , Sept. 22, 2014  Elusys Therapeutics, Inc. ... treat infectious disease, today announced it has completed ... of obiltoxaximab (ETI-204). Obiltoxaximab is an anti-toxin in ... data from these studies support the safety and ... at the intended therapeutic dose. The conclusion of ...
    (Date:9/22/2014)... , Sept. 22, 2014  Continua and ... in healthcare technology, media and telecommunications,  have formed ... China and promote international ... BHG announced this new partnership during the global ... Washington, DC , while also ...
    (Date:9/22/2014)... Sept. 22, 2014  Aethlon Medical, Inc. (OTCQB: ... to address infectious disease, cancer and other life-threatening ... Projects Agency (DARPA) has informed the Company that ... with year four of a five-year $5.9 million ... 30, 2011 under DARPA,s Dialysis-Like Therapeutics (DLT) program. ...
    Breaking Medicine Technology:Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 2Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 3Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 4Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 5Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 6Continua and Borderless Healthcare Group Form Strategic Partnership, Launch the Healthcare Technology Innovation Center in Shanghai 2Continua and Borderless Healthcare Group Form Strategic Partnership, Launch the Healthcare Technology Innovation Center in Shanghai 3Continua and Borderless Healthcare Group Form Strategic Partnership, Launch the Healthcare Technology Innovation Center in Shanghai 4Aethlon Medical Receives Notice of DARPA Contract Renewal 2Aethlon Medical Receives Notice of DARPA Contract Renewal 3Aethlon Medical Receives Notice of DARPA Contract Renewal 4
    ... , SALT LAKE CITY, Nov. 27 ... VAR ), a premier supplier of X-ray tubes and ... detectors at the RSNA Annual Meeting in Chicago, Ill. from November ... X-ray tube technology for multiple modalities as well as specialized cancer ...
    ... , CHICAGO, Nov. 27 ... annual meeting starting Sunday, Royal Philips Electronics ( PHG, AEX: ... informatics solutions designed to directly address the priorities of patients ... a desire for value, modular price points and easy upgradability. ...
    Cached Medicine Technology:Varian Medical Systems to Highlight the Latest Digital Detectors, X-ray Tubes and Cancer Treatment Technology at the Radiological Society of North America (RSNA) Annual Meeting in Chicago 2Philips Helps Hospitals Strike Balance Between Innovation and Value 2Philips Helps Hospitals Strike Balance Between Innovation and Value 3Philips Helps Hospitals Strike Balance Between Innovation and Value 4
    (Date:9/22/2014)... Hamilton, ON (September 22, 2014) McMaster scientists have ... a new class of antibiotics. , Although dozens ... looked at how a certain part of bacteria are ... stopping it. , The discovery is important as ... is making the cures for infections ineffective. The World ...
    (Date:9/22/2014)... 2014 This Flash Report is a ... needs for the Prostate Cancer market. , Download the ... strategies for any launching Prostate Cancer product:, ... an increasingly crowded market , Understanding stakeholder ... identifying community-based thought leaders and stakeholders ,Download the ...
    (Date:9/22/2014)... researchers have published a pilot study showing the ... people with multiple sclerosis (MS). Improvements were ... and pain. "Development and effectiveness of a ... Description and outcomes" was epublished ahead of print ... of MS Care (doi: 10.7224/1537-2073.2013-045). The authors ...
    (Date:9/22/2014)... New York (PRWEB) September 22, 2014 ... with the use of power morcellators ( http://www.gynecaremorcellatorlawsuit.com/ ... notes a new report detailing the continued use ... from federal regulators that specifically discouraged these procedures. ... believe that the potential cancer risks associated with ...
    (Date:9/22/2014)... HealthDay Reporter MONDAY, Sept. ... wonders: What can I do to help ensure a healthy ... prescribed may play a role in reducing the risk of ... researchers found that mothers of children with autism were significantly ... pregnancy than those whose children seem to be developing normally. ...
    Breaking Medicine News(10 mins):Health News:Download HeartBeat Experts White Paper: Stakeholder Management for new Prostate Cancer Products 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes New Report Detailing Continued Use of Uterine Morcellation Despite FDA Warning 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes New Report Detailing Continued Use of Uterine Morcellation Despite FDA Warning 3Health News:Power Morcellator News: Bernstein Liebhard LLP Notes New Report Detailing Continued Use of Uterine Morcellation Despite FDA Warning 4Health News:Could Low Iron Intake During Pregnancy Raise Autism Risk? 2Health News:Could Low Iron Intake During Pregnancy Raise Autism Risk? 3
    ... training program designed to increase empathy with their ... their interactions with the residents. This contrasts with ... drops during medical school and residency training. The ... (MGH) researchers will appear in the Journal ...
    ... immunise against serious pneumococcal disease does not offer full ... University of Gothenburg, Sweden, finding that the number of ... Each year an estimated 1 million children worldwide ... are those in poor countries, but pneumococcal bacteria cause ...
    ... be an indicator of whether a person is high-risk for ... of Colorado School of Medicine, shows people with blue eyes ... to scientists, that people with brown eyes may be less ... in which pigment loss results in irregular white patches of ...
    ... , FRIDAY, May 4 (HealthDay News) -- Thermography -- a ... for mammography -- is an unreliable cancer screen, according to ... thermography missed about 50 percent of cancers and delivered too ... Bryn Mawr Hospital in Pennsylvania. The radiation-free screening method ...
    ... News) -- Obese drivers are less likely than normal-weight drivers ... Researchers from the University at Buffalo, in New York, analyzed ... normal-weight drivers were 67 percent more likely to wear a ... a body-mass index (BMI) of 40 or higher is considered ...
    ... -- Patients with mental health emergencies wait an average of ... emergency departments, and those who are older, uninsured or intoxicated ... with psychiatric emergencies wait about 42 percent longer in the ... online May 1 in the Annals of Emergency Medicine ...
    Cached Medicine News:Health News:Brief training program improves resident physicians' empathy with patients 2Health News:Brief training program improves resident physicians' empathy with patients 3Health News:Pneumococcal disease: More cases but fewer deaths 2Health News:Eye color may indicate risk for serious skin conditions 2Health News:Mammograms Beat Thermography for Breast Cancer Detection: Study 2Health News:Mammograms Beat Thermography for Breast Cancer Detection: Study 3Health News:Obese Drivers Less Likely to Buckle Up: Study 2Health News:Psychiatric Patients Often Wait Nearly 12 Hours in ER 2
    The Optima III 45 cm line of laparoscopic hand instruments is ideal for operative laparoscopic/endoscopic procedures or when a longer instrument is needed....
    The Optima III 45 cm line of laparoscopic hand instruments is ideal for operative laparoscopic/endoscopic procedures or when a longer instrument is needed....
    The Optima III line of laparoscopic hand instruments provides a well-crafted set of instruments designed for strength and durability....
    The Optima III line of laparoscopic hand instruments provides a well-crafted set of instruments designed for strength and durability....
    Medicine Products: